Johnson & Johnson shared that its medical technology businesses – Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS – will now go by the name Johnson & Johnson MedTech. “This is the next step of Johnson & Johnson’s updated brand and visual identity announced in September 2023. This move underscores Johnson & Johnson’s leadership in medical technology with a focus on cardiovascular, orthopaedic, surgery and vision solutions. Today’s announcement has no impact on the medical technology products and solutions currently offer to customers… Partners, customers and consumers will begin to see the change come to life on social media channels and marketing materials over the coming weeks. The updated brand and visual identity will have no impact on the Johnson & Johnson MedTech portfolio,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- J&J Rybrevant/Lazcluze study shows superiority over lazertinib for NSCLC
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Cue Biopharma appoints Lucinda Warren as CBO
- Johnson & Johnson Sweetens Talc Settlement Deal by $1.1B